Almirall: launches Skilarence in Europe for psoriasis.
(CercleFinance.com) - Almirall is starting to market Skilarence in Europe for moderate-to-severe chronic plaque psoriasis, the Spanish drugmaker said on Friday.
Skilarence will first be available from today in the UK, followed by Germany, Denmark, Sweden and Norway.
For the record, Skilarence received the European Commission's approval in June.
Earlier this week Almirall presented its new corporate identity, involving a renewal of its brand image and placing greater emphasis on being a pharmaceutical company that has a strong focus on skin health.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Skilarence will first be available from today in the UK, followed by Germany, Denmark, Sweden and Norway.
For the record, Skilarence received the European Commission's approval in June.
Earlier this week Almirall presented its new corporate identity, involving a renewal of its brand image and placing greater emphasis on being a pharmaceutical company that has a strong focus on skin health.
Copyright (c) 2017 CercleFinance.com. All rights reserved.